Literature DB >> 23479230

Signaling through purinergic receptors for ATP induces human cutaneous innate and adaptive Th17 responses: implications in the pathogenesis of psoriasis.

Meaghan E Killeen1, Laura Ferris, Erine A Kupetsky, Louis Falo, Alicia R Mathers.   

Abstract

Human cutaneous dendritic cells (DCs) have the ability to prime and bias Th17 lymphocytes. However, the factors that stimulate cutaneous DCs to induce Th17 responses are not well known. Alarmins, such as ATP, likely play a pivotal role in the induction and maintenance of cutaneous immune responses by stimulating DC maturation, chemotaxis, and secretion of IL-1β and IL-6, Th17-biasing cytokines. In this study, using a well-established human skin model, we have demonstrated that signaling purinergic receptors, predominantly the P2X7 receptor (P2X7R), via an ATP analog initiate innate proinflammatory inflammation, DC17 differentiation, and the subsequent induction of Th17-biased immunity. Moreover, our results suggest a potential role for P2X7R signaling in the initiation of psoriasis pathogenesis, a Th17-dependent autoimmune disease. In support of this, we observed the increased presence of P2X7R in nonlesional and lesional psoriatic skin compared with normal healthy tissues. Interestingly, there was also a P2X7R variant that was highly expressed in lesional psoriatic skin compared with nonlesional psoriatic and normal healthy skin. Furthermore, we demonstrated that psoriatic responses could be initiated via P2X7R signaling in nonlesional skin following treatment with a P2X7R agonist. Mechanistic studies revealed a P2X7R-dependent mir-21 angiogenesis pathway that leads to the expression of vascular endothelial growth factor and IL-6 and that may be involved in the development of psoriatic lesions. In conclusion, we have established that purinergic signaling in the skin induces innate inflammation, leading to the differentiation of human Th17 responses, which have implications in the pathogenesis and potential treatment of psoriasis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23479230      PMCID: PMC3622186          DOI: 10.4049/jimmunol.1202045

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  75 in total

1.  Double anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis.

Authors:  Keehoon Jung; Donghun Lee; Hye Song Lim; Sang-Il Lee; Yeon Jung Kim; Gyun Min Lee; Sun Chang Kim; Gou Young Koh
Journal:  J Biol Chem       Date:  2011-02-23       Impact factor: 5.157

2.  P2X7 receptor positively regulates MyD88-dependent NF-κB activation.

Authors:  Yanhui Liu; Yajuan Xiao; Zhiyuan Li
Journal:  Cytokine       Date:  2011-05-28       Impact factor: 3.861

3.  Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis.

Authors:  Andrea Chiricozzi; Emma Guttman-Yassky; Mayte Suárez-Fariñas; Kristine E Nograles; Suyan Tian; Irma Cardinale; Sergio Chimenti; James G Krueger
Journal:  J Invest Dermatol       Date:  2010-11-18       Impact factor: 8.551

4.  Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R.

Authors:  Konrad Wilhelm; Jayanthi Ganesan; Tobias Müller; Christoph Dürr; Melanie Grimm; Andreas Beilhack; Christine D Krempl; Stephan Sorichter; Ulrike V Gerlach; Eva Jüttner; Alf Zerweck; Frank Gärtner; Patrizia Pellegatti; Francesco Di Virgilio; Davide Ferrari; Neeraja Kambham; Paul Fisch; Jürgen Finke; Marco Idzko; Robert Zeiser
Journal:  Nat Med       Date:  2010-11-21       Impact factor: 53.440

5.  Significance of DC-LAMP and DC-SIGN expression in psoriasis vulgaris lesions.

Authors:  Ma Wei-yuan; Liu Wen-ting; Zhao Chen; Sun Qing
Journal:  Exp Mol Pathol       Date:  2011-05-06       Impact factor: 3.362

6.  MicroRNA regulation of molecular networks mapped by global microRNA, mRNA, and protein expression in activated T lymphocytes.

Authors:  Yevgeniy A Grigoryev; Sunil M Kurian; Traver Hart; Aleksey A Nakorchevsky; Caifu Chen; Daniel Campbell; Steven R Head; John R Yates; Daniel R Salomon
Journal:  J Immunol       Date:  2011-07-25       Impact factor: 5.422

Review 7.  Significance of P2X7 receptor variants to human health and disease.

Authors:  Ronald Sluyter; Leanne Stokes
Journal:  Recent Pat DNA Gene Seq       Date:  2011-04

8.  MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression.

Authors:  Ling-Zhi Liu; Chongyong Li; Qi Chen; Yi Jing; Richard Carpenter; Yue Jiang; Hsiang-Fu Kung; Lihui Lai; Bing-Hua Jiang
Journal:  PLoS One       Date:  2011-04-22       Impact factor: 3.240

9.  MiRNA expression in psoriatic skin: reciprocal regulation of hsa-miR-99a and IGF-1R.

Authors:  Galya Lerman; Camila Avivi; Corine Mardoukh; Aviv Barzilai; Ariel Tessone; Ben Gradus; Felix Pavlotsky; Iris Barshack; Sylvie Polak-Charcon; Arie Orenstein; Eran Hornstein; Yechezkel Sidi; Dror Avni
Journal:  PLoS One       Date:  2011-06-07       Impact factor: 3.240

10.  Caspase-1 dependent IL-1β secretion is critical for host defense in a mouse model of Chlamydia pneumoniae lung infection.

Authors:  Kenichi Shimada; Timothy R Crother; Justin Karlin; Shuang Chen; Norika Chiba; V Krishnan Ramanujan; Laurent Vergnes; David M Ojcius; Moshe Arditi
Journal:  PLoS One       Date:  2011-06-23       Impact factor: 3.240

View more
  41 in total

1.  Norepinephrine and adenosine-5'-triphosphate synergize in inducing IL-6 production by human dermal microvascular endothelial cells.

Authors:  Lori L Stohl; Julie B Zang; Wanhong Ding; Michela Manni; Xi K Zhou; Richard D Granstein
Journal:  Cytokine       Date:  2013-09-08       Impact factor: 3.861

Review 2.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

Review 3.  An expanding stage for commensal microbes in host immune regulation.

Authors:  Yan Shi; Libing Mu
Journal:  Cell Mol Immunol       Date:  2017-01-09       Impact factor: 11.530

Review 4.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

5.  Differential requirement for P2X7R function in IL-17 dependent vs. IL-17 independent cellular immune responses.

Authors:  J A Sullivan; E Jankowska-Gan; L Shi; D Roenneburg; S Hegde; D S Greenspan; D S Wilkes; L C Denlinger; W J Burlingham
Journal:  Am J Transplant       Date:  2014-05-27       Impact factor: 8.086

6.  A Topical Mitochondria-Targeted Redox-Cycling Nitroxide Mitigates Oxidative Stress-Induced Skin Damage.

Authors:  Rhonda M Brand; Michael W Epperly; J Mark Stottlemyer; Erin M Skoda; Xiang Gao; Song Li; Saiful Huq; Peter Wipf; Valerian E Kagan; Joel S Greenberger; Louis D Falo
Journal:  J Invest Dermatol       Date:  2016-10-26       Impact factor: 8.551

7.  The P2X7 receptor is not essential for development of imiquimod-induced psoriasis-like inflammation in mice.

Authors:  Nicholas J Geraghty; Kylie J Mansfield; Stephen J Fuller; Debbie Watson; Ronald Sluyter
Journal:  Purinergic Signal       Date:  2017-06-08       Impact factor: 3.765

Review 8.  Development and survival of Th17 cells within the intestines: the influence of microbiome- and diet-derived signals.

Authors:  Joseph H Chewning; Casey T Weaver
Journal:  J Immunol       Date:  2014-11-15       Impact factor: 5.422

9.  Extracellular ATP and IL-23 Form a Local Inflammatory Circuit Leading to the Development of a Neutrophil-Dependent Psoriasiform Dermatitis.

Authors:  Julio A Diaz-Perez; Meaghan E Killeen; Yin Yang; Cara D Carey; Louis D Falo; Alicia R Mathers
Journal:  J Invest Dermatol       Date:  2018-06-02       Impact factor: 8.551

10.  Skin-resident T cells sense ultraviolet radiation-induced injury and contribute to DNA repair.

Authors:  Amanda S MacLeod; Ross Rudolph; Ross Corriden; Ivan Ye; Olivia Garijo; Wendy L Havran
Journal:  J Immunol       Date:  2014-05-07       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.